Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 237

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Deep learning for drug response prediction in cancer

Baptista, Delora, Ferreira, Pedro G, Rocha, Miguel · 2021 · Briefings in Bioinformatics

Abstract

Predicting the sensitivity of tumors to specific anti-cancer treatments is a challenge of paramount importance for precision medicine. Machine learning(ML) algorithms can be trained on high-throughput screening data to develop models that are able to predict the response of cancer cell lines and patients to novel drugs or drug combinations. Deep learning (DL) refers to a distinct class of ML algorithms that have achieved top-level performance in a variety of fields, including drug discovery. These types of models have unique characteristics that may make them more suitable for the complex task of modeling drug response based on both biological and chemical data, but the application of DL to drug response prediction has been unexplored until very recently. The few studies that have been published have shown promising results, and the use of DL for drug response prediction is beginning to attract greater interest from researchers in the field. In this article, we critically review recently published studies that have employed DL methods to predict drug response in cancer cell lines. We also provide a brief description of DL and the main types of architectures that have been used in these studies. Additionally, we present a selection of publicly available drug screening data resources that can be used to develop drug response prediction models. Finally, we also address the limitations of these approaches and provide a discussion on possible paths for further improvement. Contact: mrocha@di.uminho.pt

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/bib/bbz171

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 74

  1. Yang, 2013, Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells, Nucleic Acids Res, 41, D955, 10.1093/nar/gks1111 · DOI · Paper page
  2. Basu, 2013, An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules, Cell, 154, 1151, 10.1016/j.cell.2013.08.003 · DOI · Paper page
  3. Iorio, 2016, A landscape of pharmacogenomic interactions in cancer, Cell, 166, 740, 10.1016/j.cell.2016.06.017 · DOI · Paper page
  4. Menden, 2674, Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen, Nat Commun, 10, 2019
  5. Huang, 2017, Open source machine-learning algorithms for the prediction of optimal cancer drug therapies, PLoS One, 12, 1, 10.1371/journal.pone.0186906 · DOI
  6. Costello, 2014, A community effort to assess and improve drug sensitivity prediction algorithms, Nat Biotechnol, 32, 1202, 10.1038/nbt.2877 · DOI · Paper page
  7. Gönen, 2014, Drug susceptibility prediction against a panel of drugs using kernelized Bayesian multitask learning, Bioinformatics, 30, 556, 10.1093/bioinformatics/btu464 · DOI
  8. Cortés-Ciriano, 2015, Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel, Bioinformatics, 32, 85, 10.1093/bioinformatics/btv529 · DOI
  9. Gayvert, 2017, A computational approach for identifying synergistic drug combinations, PLoS Comput Biol, 13, 10.1371/journal.pcbi.1005308 · DOI
  10. Menden, 2013, Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties, PLoS One, 8, 10.1371/journal.pone.0061318 · DOI · Paper page
  11. Kalamara, 2018, How to find the right drug for each patient? Advances and challenges in pharmacogenomics, Curr Opin Syst Biol, 10, 53, 10.1016/j.coisb.2018.07.001 · DOI
  12. Goh, 2017, Deep learning for computational chemistry, J Comput Chem, 38, 1291, 10.1002/jcc.24764 · DOI · Paper page
  13. Korotcov, 2017, Comparison of deep learning with multiple machine learning methods and metrics using diverse drug discovery data sets, Mol Pharm, 14, 4462, 10.1021/acs.molpharmaceut.7b00578 · DOI · Paper page
  14. Brunton, 2011, Goodman and Gilman’s The Pharmacological Basis of Therapeutics
  15. Srivastava, 2014, Dropout: a simple way to prevent neural networks from overfitting, J Mach Learn Res, 15, 1929
  16. Tallarida, 2011, Quantitative methods for assessing drug synergism, Genes Cancer, 2, 1003, 10.1177/1947601912440575 · DOI · Paper page
  17. Mohri, 2012, Foundations of Machine Learning
  18. Lo, 2018, Machine learning in chemoinformatics and drug discovery, Drug Discov Today, 23, 1538, 10.1016/j.drudis.2018.05.010 · DOI · Paper page
  19. Duvenaud, 2015, Convolutional networks on graphs for learning molecular fingerprints, J Chem Inf Model, 56, 399
  20. Goodfellow, 2016, Deep Learning
  21. Bengio, 2013, Representation learning: a review and new perspectives, IEEE Trans Pattern Anal Mach Intell, 35, 1798, 10.1109/TPAMI.2013.50 · DOI · Paper page
  22. Kingma, 2015, A method for stochastic optimization. In: 3rd International Conference on Learning Representations, ICLR 2015, San Diego, CA, USA, May 7-9, 2015, Conference Track Proceedings
  23. Salakhutdinov, 2009, Deep Boltzmann machines. In: Proceedings of the Twelfth International Conference on Artificial Intelligence and Statistics, AISTATS 2009, Clearwater Beach, Florida, USA, 448
  24. Preuer, 2018, DeepSynergy: predicting anti-cancer drug synergy with deep learning, Bioinformatics, 34, 1538, 10.1093/bioinformatics/btx806 · DOI · Paper page
  25. Ching, 2018, Opportunities and obstacles for deep learning in biology and medicine, J R Soc Interface, 15, 10.1098/rsif.2017.0387 · DOI · Paper page
  26. Cortés-Ciriano, 2019, KekuleScope: prediction of cancer cell line sensitivity and compound potency using convolutional neural networks trained on compound images, J Chem, 11, 41, 10.1186/s13321-019-0364-5 · DOI
  27. Lipton, 2015, A Critical review of recurrent neural networks for sequence, Learning
  28. Ding, 2018, Precision oncology beyond targeted therapy: combining omics data with machine learning matches the majority of cancer cells to effective therapeutics, Mol Cancer Res, 16, 269, 10.1158/1541-7786.MCR-17-0378 · DOI · Paper page
  29. Li, 2019, DeepDSC: a deep learning method to predict drug sensitivity of cancer cell lines, IEEE/ACM Trans Comput Biol Bioinform, 1
  30. Chiu, 2019, Predicting drug response of tumors from integrated genomic profiles by deep neural networks, BMC Med Genomics, 12, 10.1186/s12920-018-0460-9 · DOI · Paper page
  31. Chen, 2018, Predict effective drug combination by deep belief network and ontology fingerprints, J Biomed Inform, 85, 149, 10.1016/j.jbi.2018.07.024 · DOI
  32. Chollet, 2015, Keras
  33. Ramsundar, 2019, Deep Learning for the Life Sciences
  34. Shoemaker, 2006, The NCI60 human tumour cell line anticancer drug screen, Nat Rev, 6, 813, 10.1038/nrc1951 · DOI · Paper page
  35. Greshock, 2010, Molecular target class is predictive of in vitro response profile, Cancer Res, 70, 3677, 10.1158/0008-5472.CAN-09-3788 · DOI
  36. Li, 2019, The landscape of cancer cell line metabolism, Nat Med, 25, 850, 10.1038/s41591-019-0404-8 · DOI · Paper page
  37. Haverty, 2016, Reproducible pharmacogenomic profiling of cancer cell line panels, Nature, 533, 333, 10.1038/nature17987 · DOI · Paper page
  38. Mpindi, 2016, Consistency in drug response profiling, Nature, 540, E5, 10.1038/nature20171 · DOI
  39. Gholami, 2013, Global proteome analysis of the NCI-60 cell line panel, Cell Rep, 4, 609, 10.1016/j.celrep.2013.07.018 · DOI · Paper page
  40. Lamb, 2006, The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease, Science, 313, 1929, 10.1126/science.1132939 · DOI · Paper page
  41. Litichevskiy, 2018, A library of phosphoproteomic and chromatin signatures for characterizing cellular responses to drug perturbations, Cell Syst, 6, 424, 10.1016/j.cels.2018.03.012 · DOI
  42. Gillet, 2013, The clinical relevance of cancer cell lines, JNCI J Natl Cancer Inst, 105, 452, 10.1093/jnci/djt007 · DOI · Paper page
  43. Goodspeed, 2016, Tumor-derived cell lines as molecular models of cancer pharmacogenomics, Mol Cancer Res, 14, 3, 10.1158/1541-7786.MCR-15-0189 · DOI · Paper page
  44. Zhang, 2011, International cancer genome consortium data portal—a one-stop shop for cancer genomics data, Database, 2011, bar026, 10.1093/database/bar026 · DOI · Paper page
  45. Szklarczyk, 2016, STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data, Nucleic Acids Res, 44, D380, 10.1093/nar/gkv1277 · DOI · Paper page
  46. Harding, 2018, The IUPHAR/BPS guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY, Nucleic Acids Res, 46, D1091, 10.1093/nar/gkx1121 · DOI · Paper page
  47. Cowley, 2014, Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies, Sci Data, 1
  48. Tsherniak, 2017, Defining a cancer dependency map, Cell, 170, 564, 10.1016/j.cell.2017.06.010 · DOI · Paper page
  49. Whirl-Carrillo, 2012, Pharmacogenomics knowledge for personalized medicine, Clin Pharmacol Ther, 92, 414, 10.1038/clpt.2012.96 · DOI · Paper page
  50. Eduati, 2015, Prediction of human population responses to toxic compounds by a collaborative competition, Nat Biotechnol, 33, 933, 10.1038/nbt.3299 · DOI
  51. Mermel, 2011, GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers, Genome Biol, 12, 10.1186/gb-2011-12-4-r41 · DOI · Paper page
  52. Loewe, 1926, Effect of combinations: mathematical basis of problem, Arch Exp Pathol Pharmakol, 114, 313, 10.1007/BF01952257 · DOI · Paper page
  53. Rampášek, 2019, Dr.VAE: improving drug response prediction via modeling of drug perturbation effects, Bioinformatics, 35, 3743, 10.1093/bioinformatics/btz158 · DOI · Paper page
  54. Sharifi-Noghabi, 2019, MOLI: multi-omics late integration with deep neural networks for drug response prediction, Bioinformatics, 35, i501, 10.1093/bioinformatics/btz318 · DOI · Paper page
  55. Liu, 2019, Improving prediction of phenotypic drug response on cancer cell lines using deep convolutional network, BMC Bioinformatics, 20, 10.1186/s12859-019-2910-6 · DOI · Paper page
  56. Matlock, 2018, Investigation of model stacking for drug sensitivity prediction, BMC Bioinformatics, 19, 71, 10.1186/s12859-018-2060-2 · DOI
  57. Tan, 2018, Drug response prediction by ensemble learning and drug-induced gene expression signatures, Genomics, 111, 1078, 10.1016/j.ygeno.2018.07.002 · DOI
  58. Chang, 2018, Cancer drug response profile scan (CDRscan): a deep learning model that predicts drug effectiveness from cancer genomic signature, Sci Rep, 8
  59. Xia, 2018, Predicting tumor cell line response to drug pairs with deep learning, BMC Bioinformatics, 19, 10.1186/s12859-018-2509-3 · DOI
  60. Qin, 2012, Signaling network prediction by the ontology fingerprint enhanced Bayesian network, BMC Syst Biol, 6, S3, 10.1186/1752-0509-6-S3-S3 · DOI
  61. Pulley, 2020, Using what we already have: uncovering new drug repurposing strategies in existing omics data, Annu Rev Pharmacol Toxicol, 60, 10.1146/annurev-pharmtox-010919-023537 · DOI
  62. Aliper, 2016, Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data, Mol Pharm, 13, 2524, 10.1021/acs.molpharmaceut.6b00248 · DOI · Paper page
  63. Donner, 2018, Drug repurposing using deep embeddings of gene expression profiles, Mol Pharm, 15, 4314, 10.1021/acs.molpharmaceut.8b00284 · DOI
  64. Zeng, 2019, deepDR: a network-based deep learning approach to in silico drug repositioning, Bioinformatics, 10.1093/bioinformatics/btz418 · DOI · Paper page
  65. Xu, 2017, Seq2seq Fingerprint, 285
  66. Hop, 2018, Geometric deep learning autonomously learns chemical features that outperform those engineered by domain experts, Mol Pharm, 15, 4371, 10.1021/acs.molpharmaceut.7b01144 · DOI
  67. Li, 2016, A review on machine learning principles for multi-view biological data integration, Brief Bioinform, 19, 325
  68. Safikhani, 2016, Revisiting inconsistency in large pharmacogenomic studies, F1000Res, 5, 2333, 10.12688/f1000research.9611.1 · DOI
  69. Geeleher, 2016, Consistency in large pharmacogenomic studies, Nature, 540, E1, 10.1038/nature19838 · DOI
  70. Goodfellow, 2014, Generative adversarial nets, 2672
  71. Liu, 2019, Wasserstein GAN-based small-sample augmentation for new-generation artificial intelligence: a case study of cancer-staging data in biology, Engineering, 5, 156, 10.1016/j.eng.2018.11.018 · DOI · Paper page
  72. Shrikumar, 2017, Learning important features through propagating activation differences, 3145
  73. Sundararajan, Axiomatic attribution for deep networks, 3319
  74. Alvarez Melis, 2018, Towards robust interpretability with self-explaining neural networks, 7775

Cited by

See all 237

Metadata

Authors
Baptista, D., Ferreira, P. G., & Rocha, M.
Venue
Briefings in Bioinformatics
Published
2020-01-17
Volume
22
Issue
1
Pages
360-379
ISSN
  • 1467-5463 (ISSN-L)
  • 1477-4054
OpenAlex
W3000469142
Cited by
237
References
49
FWCI
11.30
Type
journal article
Language
en
Open access
closed
Funders
  • Foundation for Science and Technology (UID/BIO/04469/2019, SFRH/BD/130913/2017)
  • BioTecNorte operation (NORTE-01-0145-FEDER-000004)
  • European Regional Development Fund

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Deep learning for drug response prediction in cancer. https://app.cochat.ai/papers/10.1093/bib/bbz171
The paper
Baptista, D., Ferreira, P. G., & Rocha, M. (2021). Deep learning for drug response prediction in cancer. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbz171

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.